If you are using or considering GLP-1s (or peptides for metabolic concerns, weight loss, or hormone optimization), you deserve to know the full picture
This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift, Yee Hui Yeo, MD, a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai and co-first author of the study said in a press release
That is worth saying plainly, because the same review this page cites (Urbina 2026) found thiamine and cobalamin deficits increase over time on GLP-1 therapy, and that in patients with rapid weight loss, persistent vomiting, or very poor oral intake, suspected thiamine deficiency is a medical urgency
That's the question on my mind this week after the FDA announced the membership of a new advisory committee that will weigh whether restrictions on several experimental peptides should be loosened
#TakeTheLead To view or add a comment, sign in BREAKING NEWS: FDA banned compounded semaglutide on April 30, citing "adequate supply." Novo Nordisk's Q1 earnings just defined what adequate means: injectable Wegovy sales are in decline, and a $1,300/month oral pill is the only thing saving the quarter
